

C4
Cont

65. (Amended) The polypeptide of claim [61] 62, wherein the amino acid sequence comprises a cysteine-rich domain.

C5

67. (Amended) The polypeptide of claim [65] 66, wherein the cysteine-rich region comprises amino acids 41 to 218 of SEQ ID NO:5.

C6

69. (Amended) The polypeptide of claim [67] 68, wherein the cysteine-rich domain comprises amino acids 41 to 90 of SEQ ID NO:5 or amino acids 138 to 218 of SEQ ID NO:5.

C7

72. (Amended) An isolated polypeptide encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:4 [or a complement thereof].

73. (Amended) An isolated polypeptide encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:6 [or a complement thereof].

79. (Amended) The polypeptide of claim [77] 78, [wherein the fragment] which comprises at least 25 consecutive amino acids of SEQ ID NO:5.

80. (Amended) The polypeptide of claim [78] 79, [wherein the fragment] which comprises at least 50 consecutive amino acids of SEQ ID NO:5.

C8

81. (Amended) The polypeptide of claim [79] 80, [wherein the fragment] which comprises at least 100 consecutive amino acids of SEQ ID NO:5.

82. (Amended) The polypeptide of claim [80] 81, [wherein the fragment] which comprises a cysteine-rich domain of SEQ ID NO:5.

83. (Amended) The polypeptide of claim [79] 80, [wherein the fragment] which comprises a cysteine-rich region of SEQ ID NO:5.

84. (Amended) The polypeptide of claim [81] 82, wherein the cysteine-rich domain comprises amino acids 41 to 90 of SEQ ID NO:5 or amino acids 138 to 218 of SEQ ID NO:5.

85. (Amended) The polypeptide of claim [80] 81, wherein the cysteine-rich region comprises amino acids 41 to 218 of SEQ ID NO:5.

C9

87. (Amended) A fusion polypeptide comprising the polypeptide of any one of claims [61, 65, 67, 71-75 and 77] 62, 66, 68, 72-76 and 78 [and a polypeptide which is heterologous to